Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subjects with chronic non-malignant pain severe enough to require continuous opioid therapy.
- Conditions
- Treatment of chronic non-malignant painMedDRA version: 6.1Level: PTClassification code 10033371
- Registration Number
- EUCTR2004-005187-24-IT
- Lead Sponsor
- JANSSEN-CILAG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary end point(s): ;Main Objective: ;Secondary Objective:
- Secondary Outcome Measures
Name Time Method